Products
Comprehensive catalog of pharmaceutical solutions. Browse categories and send inquiries directly.
All Products (882)
| Molecule | Drug Class / Mechanism | Oncology Type | Inquiry | |
|---|---|---|---|---|
Givinostat |
HDAC Inhibitor | Hematologic (Lymphoma) | ||
|
Molecule
Givinostat
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (Lymphoma)
Drug Class / Mechanism
HDAC Inhibitor |
||||
Glasdegib |
Hedgehog Pathway Inhibitor | Solid Tumour / Hematologic (AML) | ||
|
Molecule
Glasdegib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour / Hematologic (AML)
Drug Class / Mechanism
Hedgehog Pathway Inhibitor |
||||
Glecirasib |
RET / MET / KRAS / IDH Inhibitor | Solid Tumour | ||
|
Molecule
Glecirasib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
RET / MET / KRAS / IDH Inhibitor |
||||
Glofitamab |
Bispecific T-Cell Engager | Both (Solid & Hematologic) | ||
|
Molecule
Glofitamab
Therapeutic Category
Immunotherapy (Bispecific Antibody)
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
Bispecific T-Cell Engager |
||||
Glumetinib |
MET Inhibitor | Solid Tumour | ||
|
Molecule
Glumetinib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
MET Inhibitor |
||||
Golvatinib |
Multi-Kinase / Anti-Angiogenic Inhibitor | Solid Tumour | ||
|
Molecule
Golvatinib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
Multi-Kinase / Anti-Angiogenic Inhibitor |
||||
Iberdomide |
IMiD (Cereblon Modulator) | Hematologic (Multiple Myeloma) | ||
|
Molecule
Iberdomide
Therapeutic Category
Immunomodulatory Agent
Oncology Type
Hematologic (Multiple Myeloma)
Drug Class / Mechanism
IMiD (Cereblon Modulator) |
||||
Ibritumomab Tiuxetan (Y-90) |
Radiotherapeutic / Radiodiagnostic Agent | Both (Solid & Hematologic) | ||
|
Molecule
Ibritumomab Tiuxetan (Y-90)
Therapeutic Category
Radiopharmaceutical / Nuclear Medicine
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
Radiotherapeutic / Radiodiagnostic Agent |
||||
Icotinib |
EGFR / HER2 Tyrosine Kinase Inhibitor | Solid Tumour | ||
|
Molecule
Icotinib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
EGFR / HER2 Tyrosine Kinase Inhibitor |
||||
Idasanutlin |
MDM2 Inhibitor | Both (Solid & Hematologic) | ||
|
Molecule
Idasanutlin
Therapeutic Category
Targeted Therapy
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
MDM2 Inhibitor |
||||
Idelalisib |
PI3K Inhibitor | Both (Solid & Hematologic) | ||
|
Molecule
Idelalisib
Therapeutic Category
Targeted Therapy
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
PI3K Inhibitor |
||||
Ieramilimab |
Anti-LAG-3 mAb | Solid Tumour | ||
|
Molecule
Ieramilimab
Therapeutic Category
Immunotherapy (Checkpoint Inhibitor)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Anti-LAG-3 mAb |
||||
GivinostatTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (Lymphoma)
Drug Class / Mechanism
HDAC Inhibitor |
|
GlasdegibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour / Hematologic (AML)
Drug Class / Mechanism
Hedgehog Pathway Inhibitor |
|
GlecirasibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
RET / MET / KRAS / IDH Inhibitor |
|
GlofitamabImmunotherapy (Bispecific Antibody) |
|
|
Therapeutic Category
Immunotherapy (Bispecific Antibody)
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
Bispecific T-Cell Engager |
|
GlumetinibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
MET Inhibitor |
|
GolvatinibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
Multi-Kinase / Anti-Angiogenic Inhibitor |
|
IberdomideImmunomodulatory Agent |
|
|
Therapeutic Category
Immunomodulatory Agent
Oncology Type
Hematologic (Multiple Myeloma)
Drug Class / Mechanism
IMiD (Cereblon Modulator) |
|
Ibritumomab Tiuxetan (Y-90)Radiopharmaceutical / Nuclear Medicine |
|
|
Therapeutic Category
Radiopharmaceutical / Nuclear Medicine
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
Radiotherapeutic / Radiodiagnostic Agent |
|
IcotinibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
EGFR / HER2 Tyrosine Kinase Inhibitor |
|
IdasanutlinTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
MDM2 Inhibitor |
|
IdelalisibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
PI3K Inhibitor |
|
IeramilimabImmunotherapy (Checkpoint Inhibitor) |
|
|
Therapeutic Category
Immunotherapy (Checkpoint Inhibitor)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Anti-LAG-3 mAb |
|